BHAT研究课件（PPT 8页）.ppt

BHAT: Beta-blocker Heart Attack Trial Purpose To determine whether the β-blocker propranolol reduces all-cause mortality in patients with acute MI Reference β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982; 247: 1707–14.  BHAT: Beta-blocker Heart Attack Trial - TRIAL DESIGN -  Design Multicenter, randomized, double-blind, placebo-controlled Patients 3837 patients, aged 30–69 years, hospitalized with acute MI 5–21 days previously; patients with history of severe congestive heart failure excluded Follow up and primary end point Mean 25 months follow up. Primary endpoint all-cause mortality Treatment Placebo or propranolol, 60 or 80 mg three times daily BHAT: Beta-blocker Heart Attack Trial- RESULTS - Study halted early because all-cause mortality significantly less in propranolol group than placebo group (7.2 vs. 9.8%, 2P0.005) Also significant reduction in: Cardiovascular death Sudden death from arteriosclerotic heart disease Subgroups exhibited same trend of reduction in all-cause mortality with propranolol compared with placebo, with exception of patients with nontransmural infarct Although permanent early treatment withdrawal due to hypotension, gastrointestinal problems and serious ventricular arrhythmia was significantly more frequent in the propranolol group, serious side effects were uncommon BHAT: Beta-blocker Heart Attack Trial- RESULTS continued - BHAT: Beta-blocker Heart Attack Trial- RESULTS continued - BHAT: Beta-blocker Heart Attack Trial- RESULTS continued - BHAT: Beta-blocker Heart Attack Trial- RESULTS continued - BHAT: Beta-blocker Heart Attack Trial- SUMMARY - In patients with acute MI, propranolol reduced: All-cause mortality Cardiovascular death and sudden death from arteriosclerotic heart disease Benefit was independent of age, sex or infarct location (except nontransmural infarct) *